WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009140508) METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/140508    International Application No.:    PCT/US2009/043973
Publication Date: 19.11.2009 International Filing Date: 14.05.2009
IPC:
C12M 1/16 (2006.01)
Applicants: PRECISION THERAPEUTICS, INC. [US/US]; 2516 Jane Street Pittsburgh, PA 15203 (US) (For All Designated States Except US).
BROWER, Stacey [US/US]; (US) (For US Only).
RICE, Shara, D. [US/US]; (US) (For US Only).
BUECHEL, Heather, M. [US/US]; (US) (For US Only).
HANCHER, Lauren, M. [US/US]; (US) (For US Only)
Inventors: BROWER, Stacey; (US).
RICE, Shara, D.; (US).
BUECHEL, Heather, M.; (US).
HANCHER, Lauren, M.; (US)
Agent: HAYMAN, Mark; Cooley LLP 777 6th Street, NW Suite 1100 Washington, DC 20001 (US)
Priority Data:
61/053,094 14.05.2008 US
61/142,809 06.01.2009 US
Title (EN) METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS
(FR) MÉTHODES PERMETTANT DE PRÉDIRE UNE RÉPONSE D'UN PATIENT À DES INHIBITEURS EGFR
Abstract: front page image
(EN)The present invention provides methods for individualizing chemotherapy for cancer treatment, and particularly for evaluating a patient's responsiveness to one or more epidermal growth factor receptor (EGFR) inhibitors prior to treatment with such agents. Particularly, the invention provides an in vitro chemoresponse assay for predicting a patient's response to an EGFR inhibitor, such as an EGFR tyrosine kinase inhibitor or a molecule targeting the extracellular domain of EGFR.
(FR)La présente invention concerne des méthodes permettant d'individualiser la chimiothérapie pour le traitement du cancer, plus particulièrement, permettant d'évaluer la sensibilité d'un patient à un ou plusieurs inhibiteurs du récepteur du facteur de croissance épidermique (EGFR) avant un traitement au moyen de tels agents. En particulier, cette invention concerne un dosage biologique permettant des chimioréponses in vitro pour prédire une réponse d'un patient à un inhibiteur EGFR, tels qu'un inhibiteur tyrosine kinase EGFR ou une molécule ciblant le domaine extracellulaire de EGFR.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)